Advertisement
Screener

Inspire Medical Systems, Inc. (INSP) EBITDA

Inspire Medical Systems, Inc. (INSP) EBITDA

  • 2026-06-30: Basis Reported; EBITDA $4.08M*; Operating income -$514.00K; Depreciation and amortization $4.60M*.
  • 2026-03-31: Basis Reported; EBITDA $3.99M; Operating income (m); Depreciation and amortization (m).
  • 2025-12-31: Basis Reported; EBITDA $49.93M; Operating income (m); Depreciation and amortization (m).
  • 2025-09-30: Basis Reported; EBITDA $13.32M*; Operating income $9.64M; Depreciation and amortization $3.68M*.

Complete source-backed ebitda history.

Available history
2016-12-31 to 2026-03-31
Data captured

Historical EBITDA

EBITDA 3 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2026-06-30Reported$4.08M*-$514.00K$4.60M*$200.58M2.04%*$9.16M*$23.23M*$29.12M$24.70M$147.28M$2.80M
2026-03-31Reported$3.99M(m)(m)(m)1.95%$9.73M$12.85M$27.67M$25.83M$152.20M$13.69M
2025-12-31Reported$49.93M(m)(m)(m)18.56%(m)(m)(m)(m)(m)(m)
2025-09-30Reported$13.32M*$9.64M$3.68M*$224.50M5.93%*$10.44M*$68.53M*$31.77M$24.21M$158.87M$3.62M
2025-06-30Reported$98.00K*-$3.32M$3.41M*$217.09M0.05%*$9.00M*$2.68M*$34.67M$26.21M$159.52M$1.26M
2025-03-31Reported$1.56M(m)(m)(m)0.77%$8.41M-$6.70M$30.71M$27.80M$144.29M$1.17M
2024-12-31Reported$34.36M(m)(m)(m)14.33%(m)(m)(m)(m)(m)(m)
2024-09-30Reported$16.17M*$14.32M$1.85M*$203.19M7.96%*$8.01M*$52.28M*$32.40M$26.08M$130.39M$1.83M
2024-06-30Reported$6.48M*$5.10M$1.38M*$195.88M3.31%*$12.39M*-$78.00K*$29.84M$28.86M$132.08M$1.05M
2024-03-31Reported-$14.38M(m)(m)(m)-8.77%$11.70M$8.86M$24.76M$28.85M$125.62M$650.00K
2023-12-31Reported$10.11M(m)(m)(m)5.25%(m)(m)(m)(m)(m)(m)
2023-09-30Reported-$12.69M*-$13.47M$777.00K*$153.30M-8.28%*$6.99M*$3.64M*$24.38M$29.14M(m)$340.00K
2023-06-30Reported-$15.94M*-$16.60M$659.00K*$151.09M-10.55%*$4.86M*$5.09M*$24.25M$30.82M(m)$214.00K
2023-03-31Reported-$18.91M(m)(m)(m)-14.78%$3.75M-$1.34M$19.89M$25.52M(m)$216.00K
2022-12-31Reported$234,000.00(m)(m)(m)0.17%(m)(m)(m)(m)(m)(m)
2022-09-30Reported-$16.68M*-$17.19M$513.00K*$109.19M-15.28%*$3.51M*$11.00M*$19.79M$20.99M(m)$246.00K
2022-06-30Reported-$13.59M*-$14.01M$417.00K*$91.39M-14.87%*$1.42M*-$5.95M*$14.17M$14.53M(m)$142.00K
2022-03-31Reported-$15.7M(m)(m)(m)-22.62%$1.22M-$12.75M$10.00M$11.87M(m)$100.00K
2021-12-31Reported-$1.48M(m)(m)(m)-1.88%(m)(m)(m)(m)(m)(m)
2021-09-30Reported-$9.46M*-$9.80M$336.00K*$61.69M-15.34%*$1.15M*-$338.00K*$8.62M$9.61M(m)$3.00K
2021-06-30Reported-$12.24M*-$12.54M$304.00K*$52.96M-23.11%*$1.66M*-$10.11M*$7.52M$9.29M(m)$26.00K
2021-03-31Reported-$15.46M(m)(m)(m)-38.30%$1.32M-$10.40M$5.98M$8.15M(m)$23.00K
2020-12-31Reported-$6.81M(m)(m)(m)-14.80%(m)(m)(m)(m)(m)(m)
2020-09-30Reported-$9.68M*-$9.89M$212.00K*$35.84M-27.01%*$1.22M*-$8.91M*$5.21M$7.31M(m)$87.00K
2020-06-30Reported-$22.63M*-$22.81M$188.00K*$12.18M-185.72%*$381.00K*-$25.25M*$1.95M$6.06M(m)$0.00
2020-03-31Reported-$16.25M(m)(m)(m)-76.14%$255.00K-$14.78M$3.30M$5.44M(m)$0.00
2019-12-31Reported-$9.14M(m)(m)(m)-33.97%(m)(m)(m)(m)(m)(m)
2019-09-30Reported-$8.52M*-$8.65M$133.00K*$20.86M-40.83%*$1.06M*-$2.94M*$3.46M$3.62M(m)$0.00
2019-06-30Reported-$8.07M*-$8.18M$106.00K*$18.03M-44.75%*$958.00K*-$12.88M*$3.09M$2.85M(m)$0.00
2019-03-31Reported-$8.67M(m)(m)(m)-53.38%$275.00K-$10.94M$2.85M$2.60M(m)$0.00
2018-12-31Reported-$4.79M(m)(m)(m)-28.94%(m)(m)(m)(m)(m)(m)
2018-09-30Reported-$4.55M*-$4.65M$100.00K*$13.05M-34.85%*$0.00*-$3.55M*$2.47M$1.77M(m)$0.00
2018-06-30Reported-$5.54M*-$5.64M$98.00K*$10.94M-50.64%*$52.00K*-$6.13M*$2.10M$1.74M(m)$0.00
2018-03-31Reported-$5.11M(m)(m)(m)-50.84%$7.00K-$6.42M$2.29M$1.73M(m)$0.00
2017-12-31Reported-$3.74M(m)(m)(m)-37.51%(m)(m)(m)(m)(m)(m)
2017-09-30Reported-$3.57M*-$3.65M$75.00K*(m)(m)$124.00K*-$3.13M*(m)$1.18M(m)$0.00
2017-06-30Reported-$4.33M*-$4.38M$56.00K*(m)(m)$20.00K*-$4.03M*(m)$1.74M(m)(m)
2017-03-31Reported-$4.08M(m)(m)(m)-77.04%$206.00K-$5.36M(m)$1.59M(m)(m)

EBITDA 12 month

DateBasisEBITDAOperating incomeDepreciation and amortizationRevenueEBITDA marginCapital spendingOperating cash flowCost of products and servicesResearch and developmentSelling, general and administrationIncome tax expense / benefit
2025-12-31Reported$64.91M(m)(m)(m)7.12%$38.50M$116.98M$133.22M$103.17M$624.64M-$79.72M
2024-12-31Reported$42.63M(m)(m)(m)5.31%$39.12M$130.25M$122.99M$114.13M$529.61M$4.94M
2023-12-31Reported-$37.43M(m)(m)(m)-5.99%$23.63M$24.65M$96.58M$116.54M$451.96M$1.25M
2022-12-31Reported-$45.73M(m)(m)(m)-11.21%$9.10M$11.57M$66.11M$68.64M$320.69M$613.00K
2021-12-31Reported-$38.63M(m)(m)(m)-16.55%$4.67M-$20.12M$33.28M$37.35M$202.62M$72.00K
2020-12-31Reported-$55.37M(m)(m)(m)-47.99%$2.46M-$53.05M$17.62M$26.09M$127.87M$115.00K
2019-12-31Reported-$34.4M(m)(m)(m)-41.93%$2.74M-$32.85M$13.64M$12.84M$90.47M$40.00K
2018-12-31Reported-$19.99M(m)(m)(m)-39.50%$250.00K-$18.69M$10.06M$7.39M$53.53M$0.00
2017-12-31Reported-$15.72M(m)(m)(m)-55.02%$412.00K-$15.79M(m)$6.19M$32.36M$0.00
2016-12-31Reported-$17.15M(m)(m)(m)-104.40%$306.00K-$17.95M(m)$7.09M$22.68M$0.00

Similar stocks

Stock NameCountryMarket CapPE Ratio
NovoCure Ltd (NVCR)$1.886B-11.87
LEMAITRE VASCULAR INC (LMAT)United States$1.848B33.37
UFP TECHNOLOGIES INC (UFPT)United States$2.308B28.37
KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS)United States$1.535B-9.02
Alphatec Holdings, Inc. (ATEC)United States$1.531B-12.14
INTEGRA LIFESCIENCES HOLDINGS CORP (IART)United States$1.234B-193.02
ARTIVION, INC. (AORT)United States$1.123B-345.09
IRADIMED CORP (IRMD)United States$1.089B52.92
TANDEM DIABETES CARE INC (TNDM)United States$1.059B-16.57
PROCEPT BioRobotics Corp (PRCT)United States$1.001B-11.77